Table 2.
P-Values for Endpoint Pain Relief for ASA/PSE Comparisons
| Outcome | Comparison | 0–4 hours | Day 3 |
|---|---|---|---|
| Total pain relief (TOTPAR)a | ASA/PSE versus PSE | 0.019b | 0.348 |
| ASA/PSE versus ASA | 0.326 | 0.614 | |
| ASA/PSE versus Placebo | <0.001 | 0.220 | |
| Sum of pain intensity differences (SPID)a | ASA/PSE versus PSE | 0.085 | 0.205 |
| ASA/PSE versus ASA | 0.748 | 0.876 | |
| ASA/PSE versus Placebo | 0.421 | 0.946 | |
| Global pain relief | ASA/PSE versus PSE | n.a. | 0.043 |
| ASA/PSE versus ASA | n.a. | 0.828 | |
| ASA/PSE versus Placebo | n.a. | 0.078 |
n.a. not applicable.
Mann–Whitney U-test.
Primary endpoint.